Gordon C. Jayson

Alderley Park
Macclesfield, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Journal: EClinicalMedicine

Published: April 09, 2026

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Journal: British journal of cancer

Published: September 20, 2025

Participants' perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study.

Participants' perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study.

Journal: BMJ open

Published: July 14, 2025

Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study.

Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study.

Journal: Clinical colorectal cancer

Published: May 30, 2025

Homologous recombination deficiency in unselected cases of high-grade ovarian carcinoma.

Homologous recombination deficiency in unselected cases of high-grade ovarian carcinoma.

Journal: Journal of medical genetics

Published: May 05, 2025

The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.

The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.

Journal: BMC cancer

Published: July 01, 2024

Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

Journal: British journal of cancer

Published: May 26, 2024

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 09, 2024

Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.

Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: April 13, 2024

Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Journal: Cancers

Published: November 24, 2023

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 18, 2023

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.

Journal: British journal of cancer

Published: March 31, 2023

Showing 1-12 of 93

Last Updated: 09/26/2026